Fresenius Medical Care AG & Co. (FMS)
(Delayed Data from NYSE)
$25.13 USD
-0.21 (-0.83%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $25.12 -0.01 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth C Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FMS 25.13 -0.21(-0.83%)
Will FMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FMS
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing
FMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
UnitedHealth Q2 Earnings Miss Estimates on Increasing Medical Costs
Universal Health Q2 Earnings Beat on Strong Acute Care Admissions
Here's Why Fresenius (FMS) is a Strong Value Stock
Other News for FMS
Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic ...
Fresenius Medical Care: Is Trading Below Its Intrinsic Value (Buy)
Oakmark Global Concentrated Strategy Q2 2025 Commentary
Deutsche Bank Adjusts Price Target for Fresenius Medical (FMS) | FMS Stock News
Fresenius Medical price target raised by EUR 5 at Deutsche Bank